HRP20090393T1 - Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative - Google Patents

Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative

Info

Publication number
HRP20090393T1
HRP20090393T1 HR20090393T HRP20090393T HRP20090393T1 HR P20090393 T1 HRP20090393 T1 HR P20090393T1 HR 20090393 T HR20090393 T HR 20090393T HR P20090393 T HRP20090393 T HR P20090393T HR P20090393 T1 HRP20090393 T1 HR P20090393T1
Authority
HR
Croatia
Prior art keywords
carboxamide
carboxamide derivative
pharmaceutical composition
oral administration
pyrazol
Prior art date
Application number
HR20090393T
Other languages
English (en)
Croatian (hr)
Inventor
Breul Thierry
Gautier Jean-Claude
Saslawski Olivier
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of HRP20090393T1 publication Critical patent/HRP20090393T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20090393T 2003-11-10 2009-07-10 Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative HRP20090393T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0313259A FR2861992B1 (fr) 2003-11-10 2003-11-10 Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
PCT/FR2004/002875 WO2005046690A1 (fr) 2003-11-10 2004-11-09 Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3­carboxamide

Publications (1)

Publication Number Publication Date
HRP20090393T1 true HRP20090393T1 (en) 2009-08-31

Family

ID=34508418

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090393T HRP20090393T1 (en) 2003-11-10 2009-07-10 Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative

Country Status (28)

Country Link
US (2) US20060264469A1 (de)
EP (1) EP1691808B1 (de)
JP (1) JP4767171B2 (de)
KR (1) KR20060108668A (de)
CN (1) CN100528158C (de)
AR (1) AR047237A1 (de)
AT (1) ATE429227T1 (de)
AU (1) AU2004289086A1 (de)
BR (1) BRPI0416341A (de)
CA (1) CA2544413A1 (de)
CY (1) CY1110478T1 (de)
DE (1) DE602004020797D1 (de)
DK (1) DK1691808T3 (de)
ES (1) ES2325373T3 (de)
FR (1) FR2861992B1 (de)
HK (1) HK1102021A1 (de)
HR (1) HRP20090393T1 (de)
IL (1) IL175556A (de)
MA (1) MA28419B1 (de)
NO (1) NO20062609L (de)
NZ (1) NZ547763A (de)
PL (1) PL1691808T3 (de)
PT (1) PT1691808E (de)
RU (1) RU2321404C1 (de)
SI (1) SI1691808T1 (de)
TW (1) TWI280129B (de)
WO (1) WO2005046690A1 (de)
ZA (1) ZA200604451B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1880715A1 (de) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmazeutisch annehmbare lösungsvermittelnde Zusammensetzung und diese enthaltende pharmazeutische Darreichungsform
EP1920767A1 (de) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Schmelzverarbeitete Darreichungsform mit Imatinib
CN101784259B (zh) * 2007-08-21 2013-03-27 巴斯利尔药物股份公司 抗真菌组合物
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
US20130317117A1 (en) * 2010-11-24 2013-11-28 Pharmaceutics International, Inc. Self micro-emulsifying drug delivery system with increased bioavailability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059691A (en) * 1990-01-22 1991-10-22 American Cyanamid Company N-((dialkylamino)methylene)-substituted pyrazolo (1,5-A)-pyrimidine-3-carboxamides and N-((dialkylamino)methylene)-substituted-4,5-dihydropyrazolo-(1,5-A)-pyrimidine-3-carboxamides
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
SI1033128T2 (sl) * 1993-09-28 2012-02-29 Scherer Gmbh R P Izdelava mehke Ĺľelatinaste kapsule
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
AU692255B2 (en) * 1995-04-24 1998-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Self-emulsifiable formulation producing an oil-in-water emulsion
CA2221145A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
CN1092659C (zh) * 1997-03-14 2002-10-16 大塚制药株式会社 新型嘧啶衍生物
FR2761265B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
US6617426B1 (en) * 1999-06-22 2003-09-09 Merck & Co Inc Cysteinyl protease inhibitors
JP2001151669A (ja) * 1999-11-24 2001-06-05 Nippon Kayaku Co Ltd 経口用自己乳化製剤
MXPA02006324A (es) * 1999-12-23 2002-12-13 Pfizer Prod Inc Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
ATE359779T1 (de) * 2002-03-01 2007-05-15 Novagali Pharma Sa Selbstemulgierende systeme zur abgabe von taxoiden
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process

Also Published As

Publication number Publication date
KR20060108668A (ko) 2006-10-18
US20090004261A1 (en) 2009-01-01
NZ547763A (en) 2009-08-28
IL175556A (en) 2010-11-30
CY1110478T1 (el) 2015-04-29
AU2004289086A1 (en) 2005-05-26
DE602004020797D1 (de) 2009-06-04
ATE429227T1 (de) 2009-05-15
MA28419B1 (fr) 2007-02-01
PL1691808T3 (pl) 2009-09-30
EP1691808A1 (de) 2006-08-23
ZA200604451B (en) 2007-10-31
CN100528158C (zh) 2009-08-19
SI1691808T1 (sl) 2009-10-31
JP4767171B2 (ja) 2011-09-07
BRPI0416341A (pt) 2007-02-27
EP1691808B1 (de) 2009-04-22
RU2006120447A (ru) 2007-12-20
DK1691808T3 (da) 2009-08-03
WO2005046690A1 (fr) 2005-05-26
CN1925856A (zh) 2007-03-07
FR2861992B1 (fr) 2007-07-20
AR047237A1 (es) 2006-01-11
PT1691808E (pt) 2009-07-14
TWI280129B (en) 2007-05-01
FR2861992A1 (fr) 2005-05-13
RU2321404C1 (ru) 2008-04-10
ES2325373T3 (es) 2009-09-02
NO20062609L (no) 2006-06-06
JP2007516960A (ja) 2007-06-28
US20060264469A1 (en) 2006-11-23
IL175556A0 (en) 2008-04-13
HK1102021A1 (en) 2007-11-02
TW200524597A (en) 2005-08-01
CA2544413A1 (fr) 2005-05-26

Similar Documents

Publication Publication Date Title
HRP20090393T1 (en) Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative
RS49606B (sr) Farmaceutski preparat derivata n- piperidino-3- pirazolkarboksamida, njegovih soli i njihovih solvata za oralnu administraciju
BG105749A (en) Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
RS51978B (en) FUNGICID MIXTURES
BG110386A (en) USE OF ANTAGONISTS OF CENTRAL RECEPTORS OF CANNABINOIDS FOR THE RECEIPT OF MEDICINAL PRODUCTS TO FACILITATE THE STOPPING OF TOBACCO CONSUMPTION
BRPI0507005A (pt) compostos, composições farmacêuticas, uso de um composto, e, método de preparo de uma composição farmacêutica
DE69723104D1 (de) Piridin-2-yl-methylamin-derivate, verfahren zu deren herstellung und ihre verwendung als arzneimittel
PE20010992A1 (es) Formulacion de liberacion sostenida de un inhibidor de ciclooxigenasa-2
NO20085077L (no) Nye forbindelser
CA2390649A1 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
MXPA03004549A (es) Derivados de 3-arilindola y su uso como agonistas del receptor cb2.
DK1488781T3 (da) Farvningssammensætning, der omfatter 4,5-diamino-1-(beta-hydroxyethyl)-1H-pyrazol eller 4,5-diamino-1-(beta-methoxyethyl)-1H-pyrazol som oxidationsbase og 6-hydroxyindol som kobler
MA28454B1 (fr) Utilisation d'antagonistes du recepteur cb1 pour preparer une composition utile pour le traitement des maladies hepatiques
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
MEP10608A (en) Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
CL2004000520A1 (es) Mezcla herbicida que comprende derivados de 4-[4-metilsulfonil-benzoil]-1-metil-5-hidroxi-1h-pirazol(topramezona), cloquintocet y opcionalmente otro herbicida; composicion herbicida que comprende la mezcla; proceso de preparacion de la composicion y
DK1796461T3 (da) Flydende plantebeskyttelsesformuleringer, som indeholder diflufenican
RU2007138042A (ru) Фармацевтические композиции, содержащие в сочетании соединение-антагонист рецепторов каннабиноидов и нейролептическое средство
KR970702254A (ko) 에테르화합물, 그의 용도 및 그의 제조에 유용한 중간체(ether compound, use thereof, and intermediate for producing the compound)
FR2925337B1 (fr) Composition pharmaceutique contenant un derive de n-phenylpyrazole et du glycofurol, utilisation pour la preparation d'un medicament veterinaire topique pour lutter contre les puces
DK1351942T3 (da) Nye 2,3-benzodiazepinderivater og farmaceutiske sammensætninger indeholdende disse som den aktive bestanddel
TH67508S (th) จานรองโถใส่น้ำ
TH74718A (th) การใช้อนุพันธ์ของไพราโซลสำหรับการเตรียมผลิตภัณฑ์ทางยาซึ่งใช้ได้ดีในการป้องกันและการบำบัดหลอมลมอักเสบแบบเรื้อรังและโรคปอดอุดตันแบบเรื้อรัง
MY140071A (en) Stable liquid pesticide compositions
AR004657A1 (es) Composicion emulsionable para reprimir insectos que comprenden piretroides y compuestos de 1-fenil-3-ciano-pirazol como agente activo, metodo parareprimir insectos con aplicacion de dicha composicion